Pirfenidone treatment for patients with atypical liver function
US7635707B1 · kind B1 · utility
9Cited by
4References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 3, 2009 |
| Grant date | Dec 22, 2009 |
| Priority date | — |
| Expiry date | Sep 3, 2029 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.